Tesamorelin is a synthetic 44-amino-acid growth-hormone-releasing-factor analogue supplied as a lyophilised research material. It is studied in controlled laboratory models involving the growth-hormone-releasing-hormone receptor, pituitary signalling and modified peptide stability.
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
Research context
Tesamorelin is based on the 44-amino-acid sequence of human growth-hormone-releasing factor and incorporates an N-terminal trans-3-hexenoyl modification. Published receptor research describes interaction with the human growth-hormone-releasing-factor receptor, a G-protein-coupled receptor involved in pituitary signalling.
Clinical literature has examined defined pharmaceutical tesamorelin preparations in specific patient populations, including studies of body composition, metabolic markers and liver-fat endpoints. Those findings concern regulated preparations and controlled protocols; they do not establish the identity, purity, performance or suitability of the research material supplied on this page.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the compound, vial size and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied in the vial size selected above.
- Provided as a lyophilised research material.
- Keep the vial sealed and protected from moisture, heat and direct light.
- Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.
Frequently asked questions
What is Tesamorelin?
Tesamorelin is a synthetic analogue of the 44-amino-acid human growth-hormone-releasing factor sequence, modified with an N-terminal trans-3-hexenoyl group.
Which receptor is associated with Tesamorelin research?
Published research primarily associates Tesamorelin with the growth-hormone-releasing-hormone receptor, also described as the growth-hormone-releasing-factor receptor.
Is Tesamorelin the same as unmodified human GHRH?
No. It is based on the human GRF(1–44) sequence but includes an N-terminal lipid modification. The modified and unmodified materials should not be treated as interchangeable.
Which vial sizes are available?
Current selectable vial sizes and availability are shown above. These controls update automatically as variations change.
Are laboratory results available?
A shield appears beside a variation only when a published result is available. No indicator means that no product-specific result is currently displayed for that variation.
How should the material be stored?
See the Storage Guidelines tab for the current handling guidance for sealed lyophilised material and reconstituted solution.
Information reviewed 29 August 2026.
